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Currently, ultrasound (US), computed tomography (CT) and Magnetic Resonance imaging (MRI) repre-
sent the mainstay in the evaluation of pancreatic solid and cystic tumors affecting pancreas in 80e85%
and 10e15% of the cases respectively. Integration of US, CT or MR imaging is essential for an accurate
assessment of pancreatic parenchyma, ducts and adjacent soft tissues in order to detect and to stage the
tumor, to differentiate solid from cystic lesions and to establish an appropriate treatment. The purpose of
this review is to provide an overview of pancreatic tumors and the role of imaging in their diagnosis and
management.
In order to a prompt and accurate diagnosis and appropriate management of pancreatic lesions, it is
crucial for radiologists to know the key findings of the most frequent tumors of the pancreas and the
current role of imaging modalities.
A multimodality approach is often helpful. If multidetector-row CT (MDCT) is the preferred initial
imaging modality in patients with clinical suspicion for pancreatic cancer, multiparametric MRI provides
essential information for the detection and characterization of a wide variety of pancreatic lesions and
can be used as a problem-solving tool at diagnosis and during follow-up.
© 2015 Published by Elsevier Ltd on behalf of IJS Publishing Group Limited.1. Introduction
Currently, ultrasound (US), computed tomography (CT) and
Magnetic Resonance imaging (MRI) represent the mainstay in the
evaluation of pancreatic solid and cystic tumors affecting pancreas
in 80e85% and 10e15% of the cases respectively [1,2]. Integration of
US, CT or MR imaging is essential for an accurate assessment of
pancreatic parenchyma, ducts and adjacent soft tissues in order to
detect and to stage the tumor, to differentiate solid from cystic le-
sions and to establish an appropriate treatment. The purpose of this
review is to provide an overview of pancreatic tumors and the role
of imaging in their diagnosis and management.S. Cappabianca).
f of IJS Publishing Group Limited.2. Classification
Pancreatic tumors including a heterogeneous group of primary
lesions: adenocarcinoma, neuroendocrine tumor (NET), pancreatic
cystic neoplasms, solid pseudopapillary tumor, pancreatoblastoma,
pancreatic lymphoma and rare miscellaneous neoplasms [1]
(Table 1).
Pancreatic ductal adenocarcinoma (PDA) represents 85e95% of
all pancreatic solid pancreatic malignant neoplasms while neuro-
endocrine tumors are frequently benign and include insulinoma,
gastrinoma, glucagonoma, somatostatinoma, vasoactive intestinal
polypeptide tumor (VIPoma), Pancreatic polypeptide secreting tu-
mors (PPomas) and non-functioning tumors, amounting to 3e4% of
the cases [1].
3. Clinical presentation
Early pancreatic cancer is often asymptomatic. Tumors in the
Table 1
Pancreatic tumors and tumor-like lesions.
Tumor lesions Tumor-like lesions
Primitive Secondary
(from)
Focal pancreatitis
Solid exocrine tumors Solid neuroendocrine tumors
(NETs)
Cystic lesions Fatty infiltration-
replacement
Ductal
adenocarcinoma
Insulinoma Intraductal papillary mucinous neoplasm (IPMN) Renal cell
carcinoma
Pseudocysts
Acinar cell carcinoma Gastrinoma Serous cystoadenoma Lung
carcinoma
Intrapancreatic accessory
spleen
Pancreatoblastoma Glucaconoma Mucinous cystic neoplasm Breast
carcinoma
Hydatid cysts
Solid pseudopapillary
neoplasm
Vipoma True cyst Colorectal
carcinoma
Fibrocystic disease
Pancreatic lymphoma Pancreatic polypeptide secreting
tumors (PPoma)
Cystic variants of solid tumors (e.g. Cystic teratoma, Cystic ductal
adenocarcinoma, Cystic NET)
Melanoma Duplication cysts and
retention cysts
Miscellaneous
carcinomas
Somatostatinoma Ovarian
cancer
Sarcoidosis
Non-functioning tumors Sarcoma Castleman disease
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obstruction. However, tumors in the body and tail can remain
asymptomatic till late in disease stage [3].
Weight loss, poor appetite, abdominal discomfort, abdominal or
midback pain and obstructive jaundice and related symptoms are
relatively common and generally occur late in the clinical devel-
opment; pancreatitis is less common as presenting symptoms
[1,4,5]. Digestive problems, nausea and vomiting occur more
frequently when the cancer presses on the stomach. Rarely,
pancreatic cancers cause diabetes due to the destruction of insulin-
making cells. Encasement of vascular structures, infiltration of
adjacent bowel and superior mesenteric vein thrombosis may all
occur later.
PDA is associated with several rare paraneoplastic syndromes:
Trousseau syndrome is traditionally defined as migratory thrombo-
phlebitis [6,7]. Panniculitis is associated with acinar cell carcinoma
in 8% of cases; eczematous dermatitis, fibrous cutaneous hand
changes, plantar keratoderma, polymyositis, neurological and he-
matologic manifestation represent other paraneoplastic syndromes
[1,8e10].
Signs and symptoms of pancreatic functioning NET are different
and dependent on an excessive secretion of hormones. Insulinoma
(50%) reveals itself with hypoglycemic attacks featuring neuro-
glycopenia and sympathetic over-stimulation, including weakness,
confusion, sweating, and rapid heartbeat, and/or atypical seizures
[1,11e13]. Gastrinomas (20%) produce too much gastrin, causing a
condition known as Zollinger-Ellison syndrome, resulting in peptic
ulcers which can cause pain, nausea, loss of appetite and anemia
[1,11,14e17]. VIPomas (3%) make vasoactive intestinal peptide (VIP)
and result in watery diarrhea and hypokalemia [1,11,12,18]. Gluca-
gonomas (1%) produce glucagon that increases glucose levels in the
blood; most of the symptoms are often nonspecific, as diarrhea,
weight loss, malnutrition and rarely hyperglycemia. The most
distinctive feature of a glucagonoma is necrolytic migratory ery-
thema, a red rash with swelling and blisters that often travels place
to place on the skin [1,11,12,19]. Somatostatinomas (<1%) produce
somatostatin; symptoms can include diarrhea, steatorrhea, nausea,
poor appetite and weight loss, gallstones, and symptoms of dia-
betes [1,11,20]. Ppomas cause an increase in the production of
pancreatic polypeptide (PP), but they are rare and have not been
associated with any clinical syndrome [21]; some patients also get
watery diarrhea.
Signs and symptoms of non-functioning neuroendocrine tu-
mors are caused by mass effect (mainly jaundice, belly pain and
weight loss) [11].Moreover, asymptomatic cancer can be incidentally detected on
abdominal scans obtained for other reasons.
4. Imaging
4.1. Plain radiograph
Plain abdominal radiograph has a very limited role in imaging of
the pancreas; sometimes it can show coarse parenchymal calcifi-
cation of the pancreas in 25e59% of patients with chronic
pancreatitis; however, calcifications near the pancreas can be
confused with splenic artery calcifications.
4.2. Ultrasound
Ultrasound (US) is usually limited in the evaluation of pancreas
due to body habitus (adipose tissue) and the interposed intestinal
and gastric bloating [22e24]. However, US is the first non-invasive
imaging test for the evaluation of pancreas. Abdominal conven-
tional US allows to assess size, site and echogenicity of pancreatic
lesions and to evaluate the Wirsung duct caliber ;with a sensitivity
and specificity respectively of 75% [24] and an accuracy of 50e70%
[25]. Most focal pancreatic lesions are hypoechoic compared to
normal parenchyma. Typically dilatation of the common bile duct
and pancreatic duct (double duct sign), which is very suggestive for
a mass in the pancreatic head, even in the absence of a visible mass,
is seen in patients with a pancreatic head tumor.
Endoscopic US (EUS) provides ultra-high resolution images and
is commonly accepted as the most sensitive technique for detection
of small pancreatic head tumors (<2 cm) [26,27].
4.3. Contrast-enhanced US
The introduction of microbubble contrast agents has improved
the diagnostic accuracy of US in the study of pancreatic pathologies
[28,29]. Contrast-enhanced US (CEUS) is a cost-effective real-time
method that allows the evaluation of the enhancement of pancre-
atic lesions during the dynamic phases [29] and provides useful
findings for differentiating pancreatic carcinoma from chronic focal
pancreatitis [30]; moreover CEUS is very accurate in demonstrating
NET vascularisation [31].
Even if the Authors themselves suggest that CEUS is an accurate
method for the characterization of pancreatic masses [32], CEUS is
not sufficient to characterize the tumor, but rather it can improve
the accuracy of US of pancreatic lesions incidentally detected as
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or MRI allow a more accurate evaluation of the local extension and
metastatic spread [33,34]. Nevertheless, CEUS can be used during
follow-up in patients with severe acute pancreatitis, after an initial
CT evaluation, because it may help in identifying and in delineating
necrotic areas, which do not enhance [28,35].
Technique e After contrast agent injection, enhancement of the
pancreas begins immediately after aortic enhancement during an
early arterial phase (10e30 s); subsequently there is a transient
venous phase (30 to approximately 120 s) [28]. The main limitation
is represented by the different pharmacokinetics of microbubble
contrast agents in comparison to the contrast medium of CT or MRI,
due to their confine in vessel lumen without extravascular phase;
consequently the late phase of CEUS does not correspond to the
interstitial or parenchymal equilibrium phase described in CT and/
or MRI [23].
4.4. Multidetector-row CT
Multidetector-row Computed Tomography (MDCT) is the most
widely used imaging modality for pancreatic tumors evaluation
with a sensitivity between 76% and 92% for diagnosing pancreatic
cancer [3,36,37]. Brennan et al. assert that CT has an accuracy of
85e95% for tumor detection, a positive predictive value of 89e100%
for unresectability and a negative predictive value of 45e79% for
resectability [38].
MDCT allows to accurately assess tumor morphology, ductal
anatomy, and its relationship to surrounding organs and vascular
structures, permitting a surgical planning. High-resolution MDCT
and image-processing techniques (multiplanar reconstructions and
curved reformations) can provide additional details and can define
the pancreatic ductal course and anatomy. CT is also easily able to
detect the “double duct sign”, whereas tumors in the pancreatic
body may cause upstream MPD dilatation.
Since the tumor may be isoattenuating, no pancreatic mass is
visualized in 10% of cases [38].
Indirect signs, such as abrupt cut-off of the pancreatic duct PDA
dilation (interrupted duct sign), mass effect on the pancreatic pa-
renchyma and atrophic distal parenchyma, should be considered as
indicators of tumors when mass cannot be clearly identified on CT
[39]; the knowledge of pancreatic cancer and surrounding paren-
chyma at CT is essential to improve research on methods to detect
isoattenueted tumor [40]. The quantitative analysis at triphasic
MDCT increases tumor detection with respect to visual analysis,
showing a higher sensitivity in all phases, even for small PDAs
isodense to the pancreatic parenchyma upstream to the tumor [40].
Technique e Many CT protocols for pancreatic enhancement
and pancreatic tumor staging are described in the literature. In
patients with suspected pancreatic tumor, the maiority of standard
CT protocols [41e44] involves non-contrast study followed by
pancreatic parenchymal phase (PPP) and portal venous phase (PVP)
and delayed phase (DP), after the administration of intravenous
contrast material.
An arterial phase (AP) may be performed if a hypervascular
pancreatic lesion such as a neuroendocrine tumor is suspected,
while PPP (typically 40e45 s after start of contrast injection at flow
rate of 4 ml/s) allows maximal differentiation between the normal
parenchyma and the hypodense pancreatic lesions, becoming the
most sensitive phase for the evaluation of pancreatic parenchyma
(e.g. adenocarcinoma) [37,41]. PVP (70 s after start of contrast in-
jection) is optimal for detecting liver metastases.
Nevertheless, multiphase CT exposes patient to a high radiation
dose. Recently, the split-bolus CT protocol has been proposed for
the detection and staging of pancreatic cancer [45].
Split-bolus MDCT technique, combining arterial phase (AP) andPVP, allows an optimal pancreatic enhancement to detect normal
pancreatic parenchyma and to maximize the difference in attenu-
ation between the tumor and the background pancreatic paren-
chyma with a better tumor conspicuity, provides optimal
synchronous arterial and mesenteric venous opacification evalu-
ating potential tumor resecability, and reduces radiation dose
[45e47]. In addition, split-bolus allows lymph nodes assessment,
detection and characterization of the focal liver lesions [46].
In Fig. 1 is reported a schematic view of split-bolus MDCT pro-
tocol in a patient weighting 75 Kg.
4.5. MRI
MRI, including morfologic and functional sequences, has
become widely used in the diagnosis of pancreatic pathologies
because of its very high soft-tissue contrast resolution, with an
accuracy in the detection and staging of adenocarcinoma of
90e100% [48]; MR cholangiopancreatography (MRCP) permits the
evaluation of pancreatic ductal system anatomy and abnormalities
and can be used to depict relationship between cystic lesions and
pancreatic duct [49,50]. MRI is used as a problem-solving tool for
diagnosis and during follow-up in patients with cystic pancreatic
tumors [51].
Furthermore, diffusion-weighted imaging (DWI), almost be-
comes part of theMRI protocol, may provide additional information
about a wide variety of solid and cystic lesions of the pancreas and
can help radiologists, especially to detect solid pancreatic tumors
with a high cellularity or fibrosis, which show a low ADC (apparent
diffusion coefficient) values [49], and potentially to distinguish
focal pancreatitis from adenocarcinoma, as reported in literature
[52].
MRI can be performed with scanning at 1.5T or 3T: studies
comparing 1.5T and 3T abdominal MRI suggest that 3T does not
offer substantial improvement in image quality for unenhanced
images; however, the signal-noise ratio (SNR) of contrast-enhanced
images is thought to be superior at 3T [52e60].
Technique e A complete evaluation of the pancreas and the
pancreato-biliary ductal system includes a multiparametric MRI
(mpMRI) T2-weighted (T2W) and diffusion-weighted imaging
(DWI), as well as contrast-enhanced MRI and cholangio-
pancreatography (MRCP) pulse sequences (HASTE) using the
following sequences: axial T1W gradient-echo, with and without
fat saturation, using breath-hold or gated respirations, axial and
coronal T2W images with and without fat saturation, either fast
spin echo (FSE) or turbo spin echo (TSE), T1W breath-hold fat-
suppressed 3D gradient-echo images before and after gadolinium
(Gd-DTPA) administration and spin echo EPI single shot (DWI) with
b value 0, 800, 1000 and ADC maps reconstruction. Contrast-
enhanced MRI includes multiphase (PPP, PVP and DP) study after
intravenous administration of Gd-DTPA.
The MRCP sequences can be obtained by 3-dimensional (3D)
acquisition that produces high resolution images of the pancreato-
biliary ductal system. Pineapple and blueberry juice have been used
as oral contrast agents to reduce the signal from the overlying
stomach and duodenum.
Secretin MR cholangiopancreatography (S-MRCP) sequence,
which entails administration of secretin to stimulate the exocrine
function of the pancreas, have been developed for a more complete
assessment of pancreatic ducts and glandular function, useful in
assessment of complex ductal anomalies and to quantitatively
assess the exocrine function of the pancreas [50].
4.6. PET/CT
Nuclear medicine is able to provide a functional imaging of
Fig. 1. Schematic view of split-bolus MDCT technique of the chest, abdomen and pelvis shows contrast medium administration splitted into two-bolus injections in adult male
(weighted 70 kg). First bolus [at the start of bolus injection (or time zero): 84 ml (1.2 ml/kg) of contrast medium at 2.0 ml/s, followed by 20 ml of saline solution at same flow rate, is
injected to obtain adequate hepatic enhancement during the portal venous phase; second bolus: 60 ml of contrast medium at 3.5 ml/s followed by 20 ml of saline solution at the
same flow rate to obtain hepatic arterial phase. CT scanning is started 6e8 s after to time of arrival of contrast medium at the aorta (Tarr) determined by bolus tracking technique
(raising the threshold value at 500 HU) with a circular region of interest placed in the descending aorta. A single contrast-enhanced acquisition from the pulmonary apex to the
pubic symphysis was carried-out, resulting in a simultaneous contrast enhancement of the arterial and venous systems.
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pivotal importance to better diagnose and follow up pancreatic
lesions.
Many papers investigated the diagnostic ability of pancreatic
cancer of Positron Emission Tomography (PET) with 2-deoxy-[18F]
fluoro-D-glucose (18FDG), a radiocompound labelled with 18Fluo-
rine (18F) that uses glycolytic pathways and has an uptake mecha-
nism in tumour cells depending on the increased number of
functional glucose transporters and glycolytic enzymes [61e62].
The wide diffusion of hybrid systems, combining nuclear medicine
(SPECT and PET) and radiology devices (CT, MRI) mounted on the
same gantry to obtain co-registered and fused functional and
anatomical images, improves diagnostic results in clinical practice
[61,62]. In a recent meta-analysis the sensitivity and specificity of
18FDG-PET to confirm suspected pancreatic cancer resulted up to
95% and 100%, respectively [62].
A further promising radiopharmaceutical has been proposed to
image pancreatic cancer, the thymidine analogue 3-deoxy-30-[18F]
fluorothymidine (18FLT) [63]. This radiocompound allows to visu-
alize proliferating lesions and it has been shown that it selectively
accumulates in malignant tumours of the pancreas [64], but its use
is still limited.
Furthermore pancreas is a site of neuroendocrine tumours
(NETs). Pancreatic NETs are less frequent than endocrine gastroin-
testinal tumours and, although generally asymptomatic, they may
cause hypersecretion of several hormones (gastrin, insulin,
glucagon, vasoactive intestinal peptide) and usually over-express
somatostatin receptors (SSR) 1e5 [65e68].
Among positron emitting radiopharmaceuticals 18FDG does not
represent the option of choice because it better detects highly
metabolic undifferentiated tumours, while other radiotracers such
as 18F-DOPA (3,4-dihydroxy-L-phenylalanine labelled with 18F) and
peptides labelled with 68Ga provide better results [69]. NETs are
avid of 18F-DOPA because they derive from cells belonging to the
amine precursor uptake and decarboxylation (APUD) cell system
and therefore showa high L-DOPA decarboxylase activity [70] while
68Ga-DOTA peptides are radiolabelled somatostatin analogues
binding to somatostain receptors (SR) that are over-expressed on
NET tumour cell surface [71].
The most known PET tracer for SR imaging are [68Ga-DOTA0,-
Tyr3]octreotate (68Ga-DOTATATE), 68Ga-DOTA0,Tyr3]octreotide
(68Ga-DOTATOC) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid]-1-Nal3-octreotide (68Ga-DOTANOC) and they are
useful to evaluate SR expression in order to treat the patients with
b-emitting labelled somatostatin analogues [61,71], such asradiocompounds labelled by 90Yttrium (90Y) and 177Lutetium
(177Lu).
Despite the clinical relevance of 68Ga-labelled radiocompounds
also due to the high spatial resolution of PET scan comparing with
SPECT, the g-emitting somatostatin analogues maintain a certain
role. 111In-DTPA-octreotide is commercially available and is the
most commonly used agent for SR imaging [71,72]. It shares with
positron-emitting radiopharmaceuticals the clinical indications
including the diagnosis of primary andmetastatic NETs, the staging
and the follow-up of patients and the selection of subjects with
inoperable and/or metastatic tumours candidates to peptide re-
ceptor radionuclide therapy.
5. Solid lesions
5.1. Pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDA), 85e95% of all
pancreatic solid pancreatic malignant neoplasms, represents the
fourth leading cause to cancer-related deaths and affects menmore
frequently between 60 and 80 years of age [1e4]. PDA is located in
the pancreatic head 60e70%, less commonly in the body (10e20%)
and 5e10% in the tail [1e3]. Postoperative survival rate at 5-year is
of 20% [1,3], furthermore the cancer is resectable at diagnosis in
only about 20e15% of cases [50]. CA 19.9 can be elevated, but it is
useful during follow-up because its rise up precedes imaging
manifestation of relapse [50].
On PPP of the conventional bi- or triphasic CT and on mixed
(PPP/PVP) phase of split-bolus MDCT protocol, most tumors are
hynomogeneous hypoattenuating after intravenous contrast me-
dium injection (Fig. 2); the 10% of cases may be isoattenuating
[1,38,40]: mass effect, abnormal contour of the pancreas, ductal
obstruction with “double duct sign”, and vascular invasion (vessel
deformity, thrombosis, and development of collateral vessels) are
indirect signs of pancreatic cancer [1,2]. Rarely (8% of cases) can be
see cystic-necrotic degeneration [73].
At MRI PDA shows low signal intensity on T1W images and
appears hypovascular than the normal pancreas after paramagnetic
contrast medium administration; sometimes exhibit delayed
enhancement [49]. On dynamic images the PPP allows the greatest
attenuation difference between cancer and normal pancreatic pa-
renchyma; T2W images shows less tumor conspicuity, furthermore
is useful to emphasize secondary signs as upstream pancreatic
ductal dilatation.
In addition to morphological and multiphasic contrast-
Fig. 2. 60-years-old male patient with unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial 64-slice split-bolus CT protocol. Mixed phase (a) and delayed
phase (b) show inhomogeneous lesion in the body of the pancreas. Note dilatation of the Wirsung in the pancreas up-stream to the tumor.
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by DWI further improve MRI diagnostic accuracy [74,75]. Since
malignant tumors are characterized by limited diffusion due to
fibrosis and hypercellularity, DWI and apparent diffusion coeffi-
cient (ADC) values provide a high degree of contrast between PDA
and normal pancreatic parenchyma: pancreatic tumours have
increased signal intensity on diffusionweighted images with high b
values (b > 500 s/mm2) and relatively low ADC values [49]. In
addition, DWI may be helpful in the earlier detection of cancer and
lymph nodes and/or liver metastases [49,76e78]. Instead, it is
difficult to differentiate between mass-forming focal pancreatitisFig. 3. 28-years-old male patient with pancreatic ductal adenocarcinoma with multiple live
slightly inhomogeneous hyperintense lesion (arrow in a) in the body of the pancreas determi
the interrupted duct sign (head arrow in b). At multiphase T1W breath-hold fat-suppresse
(cef) the lesion appears inhomogeneous with maximum enhancement on delayed phase (f)
restriction of the diffusion of the water molecules.and poorly differentiated PDA [49].
Representative case of PDA evaluated by mpMRI is reported in
Fig. 3.
Endoscopic US, specially used to perform biopsies, plays a key
role in the detection and staging of small tumors (up to 0.2 cm) and
clarify equivocal cases at CT or MRI showing an ill-defined, het-
erogeneous hypoechoic mass [1].
On 18FDG PET evaluation PDA generally shows intense focal FDG
uptake due to enhanced glucose metabolism. 18FDG PET is poten-
tially useful to detection small metastases that can be underesti-
mate at MDCT and MRI.r metastasis at 3T mpMRI evaluation. Fat-suppressed T2-weighted images (a) shows a
ning dilatation of the Wirsung in the pancreas up-stream to the tumor. MRCP (b) shows
d 3D gradient-echo images after intravenous administration of gadolinium (Gd-DTPA)
. On DWI with b ¼ 1000 values (g) and ADC map (h) the tumor (arrow in g and h) show
Fig. 4. 79-years-old male patient with neuroendocrine pancreatic tumor (NET) on
pancreatic at 64-slice CT. Pancreatic parenchymal phase show well defined lesion with
intense enhancement at the isthmus of the pancreas.
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Pancreatic neuroendocrine tumors (NET) represent about 1%e
5% of all pancreatic tumors and occur sporadically in patients in
their third to sixth decades [79]. In some cases, association with
multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis
type 1, von Hippel-Lindau syndrome and tuberous sclerosis can
been observed.
The NET often shows a homogeneous or heterogeneous hyper-
enhancing pattern at the early stage in CEUS, depending on theFig. 5. 54-years-old female patient with functioning neuroendocrine pancreatic tumor (NET
hyperintense on T2W images (b). MRCP (c) shows interruption of the Wirsung (head arrow
intravenous administration of gadolinium (Gd-DTPA) (def) the lesion exhibits intense enhan
(arrow in e and f). On DWI with b ¼ 1000 values (g) and ADC map (h) the tumor (arrow inamount of the stroma within the lesion [80e82].
On AP or PPP of the conventional bi- or triphasic MDCT and in
mixed (PPP/PVP) phase of split-bolus MDCT protocol, the NET ap-
pears hyperattenueted in comparison to adjacent pancreatic pa-
renchyma. Small NET (<2 cm) shows typical homogeneous intense
enhancement during the arterial phase whereas greatest lesions
show heterogeneous enhancement, a finding due to areas of cystic
degeneration, necrosis, fibrosis and calcification [1,83,84].
NET are usually more conspicuous on T1-weighted images; the
presence of cystic component (necrosis or cystic degeneration) are
typically hyperintense on T2 MRI. Malignant NET may show high
signal intensity on DWI with high b values and low ADC values due
to restriction by dense tumor cellularity; benign small NETcan have
a relatively high ADC values [49].
As previously reported pancreatic NET can be successfully
evaluated by imagingwith somatostatin analogues labeled by g and
b-emitting radiopharmaceuticals, while 18FDG can be used to
evaluate more aggressive and less differentiated tumors.
Representative cases of functional and non-functional NET (US,
split-bolus MDTC, mp-MRI) are reported in Figs. 4e6.
5.3. Solid pseudopapillary tumor
Solid pseudopapillary tumor (SPT), most commonly localized in
the pancreatic tail and in young females, constitute approximately
1%e2% of all pancreatic neoplasms [85,86], with an excellent
prognosis following complete resection. Rarely malignant degen-
eration can occur, just as in liver and peritoneummetastases [1,87].
On CT, SPT usually can be seen as a large well-encapsulated
mass with cystic, solid or hemorrhagic components [1,82,88]) at 3T mpMRI evaluation. The lesion appears hypointense on T1W images (a), slightly
in c). At multiphase T1W breath-hold fat-suppressed 3D gradient-echo images after
cement in arterial phase (arrow in a) which persists during venous and delayed phase
g and h) shows restriction of the diffusion of the water molecules.
Fig. 6. 34-years-old male patient with incidental finding of non-functioning pancreatic neuroendocrine tumor (arrow). Mixed phase at 64-slice split-bolus CT protocol (a) shows a
well defined lesion that exhibits intense enhancement which persists into the delayed phase (b) in the tail of the pancreas. US (c) shows a hypoechoic lesion and CEUS (d)
demonstrates hyperenhancing pattern at the early phase. At 3T MRI evaluation on T2W images the NET appears as slightly inhomogeneous hyperintense lesion (e) that exhibits
intense enhancement at arterial phase T1W breath-hold fat-suppressed 3D gradient-echo images after intravenous administration of gadolinium (Gd-DTPA) (f). On DWI with
b ¼ 1000 values (g) and ADC map (h) the tumor (arrow in g and h) shows restriction to water diffusion due to increased cellular density.
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bile duct or pancreatic duct; peripheral calcification can be seen in
30% of cases [86]. The pseudocapsule (compressed pancreatic
tissue and fibrosis) is an important feature to distinguish these
neoplasms.
After contrast medium injection, the SPT shows peripheral slow
early heterogeneous enhancement during arterial phase of solid
component with central cystic spaces [85].
MRI demonstrates the small tumors, most frequently func-
tioning tumors, as solid and homogeneous and larger tumors, most
frequently nonfunctioning tumors, as heterogeneous mass with anheterogeneous signal intensity on T1-and T2W images. The degree
of diffusion and ADC values are dependent to cystic or hemorrhagic
fluid; solid component usually can show relatively low ADC values
[49].
Most of the papers on 18FDG PET in pancreatic tumours concern
PDA, but a recent interesting paper [89] retrospectively reviewed
the records of 11 subjects with SPT and 46 patients with pancreatic
ductal adenocarcinoma, showing high 18FDG uptake also in SPT and
concluding that this rare tumour should be consideredwhen a solid
pancreatic mass with increased 18FDG uptake is revealed at PET/CT
scan.
Fig. 7. 29-years-old female patient with serous cystadenoma. Mixed phase at 64-slice Split-bolus CT protocol (a) and delayed phase (b) show a cystic lesion with polycyclic contours
and some thin internal septa with no significant enhancement in the head of the pancreas. 3T MRI on T1W (c) and fat suppressed T2W images (d) confirm the cystic formation. At
multiphase T1W breath-hold fat-suppressed 3D gradient-echo images after intravenous administration of gadolinium (Gd-DTPA) (eeg) thin internal septa doesn't exhibit sig-
nificant enhancement. On DWI with b ¼ 1000 values (h) and ADC map (i) the lesion not demonstrated restriction of the diffusion of the water molecules.
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Pancreatoblastoma, the most common pancreatic tumor in
young children (mean 5 years), is rare in adults (<1% of all
pancreatic tumors) [49,90]. Pancreatoblastoma is typically an
asymptomatic, well-encapsulated and heterogeneous largemass; it
coexists with an increase of serum alpha-fetoprotein level in
25e33% of cases [1]. Metastases are rare.
This tumor is heterogeneous with hypoechoic cystic spaces and
hyperechoic internal septa at US evaluation [91].
OnMRI pancreatoblastoma shows intermediate signal intensity
at T1-and T2-weighted with small hyperintense areas in T2. Thesolid component exhibits rapid enhancement during arterial
phase and wash-out in delayed phase after contrast medium
administration and restricted diffusion due to dense cellularity on
DWI [85].
5.5. Pancreatic lymphoma
Primary pancreatic lymphoma, most frequent in immunocom-
promised patients, constitutes 0.5% of pancreatic tumors and is
most commonly a B-cell subtype of non-Hodgkin lymphoma [1,92].
More common is a secondary lymphoma as result of direct exten-
sion from peripancreatic lymphadenopathy. Clinical presentation
Fig. 8. 37-years-old female patient with macrocystic serous cystadenoma at 1.5 T MRI. T2W images (a), MRCP (b), and MRCP sequences with 3D reconstruction (c) show a well-
defined voluminous cystic lesion with internal septa and marked dilatation of the main pancreatic duct and the lateral ducts. The internal septa of the lesion exhibit progressive
enhancement on multiphase T1W breath-hold fat-suppressed 3D gradient-echo images after intravenous administration of gadolinium (Gd-DTPA) (def).
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findings were abdominal pain and weight loss.
Pancreatic lymphoma occurs in a focal well-circumscribed form
(uniform low attenuation and minimal enhancement at CT; hypo-
intensity on T1W images and intermediate signal intensity on T2W
images and slight contrast enhancement at MRI) and a diffuse
pattern (diffuse enlargement and hypointensity on T1-and T2 w
images and moderate homogeneous enhancement at MRI) that can
simulate the appearance of acute pancreatitis [1,93]. Imaging
findings can show encasement of peripancreatic vessels [94].
Imaging findings are not specific in the differentiation of
pancreatic lymphoma and pancreatic cancer, but a bulky homo-
geneous tumoral mass without alteration of Wirsung's duct should
suggest the diagnosis [95].Fig. 9. 56-years-old female patient with mucinous adenocarcinoma of the pancreas. Panc
lesions in the head/uncinate process of the pancreas. CT of the chest show multiple diffuse
MRCP imaging with 3D reconstruction was demonstrated (d).6. Cystic lesions
Cystic lesions represents 10e15% of all pancreatic tumors. An
important distinction among neoplastic cysts is the categorization
into four subtypes unilocular, macrocystic: multilocular, micro-
cystic and cystic with a solid component and in mucinous versus
nonmucinous. The first aim of imaging is to characterize cystic
neoplasms, to confirm or to exclude a communication between the
cystic lesion and the pancreatic duct and to distinguish these from
pseudocysts (encapsulated fluid collections without necrosis after 4
week from onset of acute pancreatitis) [96].
When small (<3 cm) cysts are represented by unilocular lesions,
well defined and without internal septa, calcification or internal
soft-tissues nodules, it is suggested a close surveillance with serialreatic parenchymal phase (a) and portal-venous phase (b) at MDCT show hypodense
bilateral parenchymal metastasis (c). No communication with pancreatic duct at 1.5T
Fig. 10. 36-years-old female patient with main-duct intraductal papillary mucinous neoplasm. Axial (a) and coronal multiplanar reconstruction (b) mixed phase at 64-slice split-
bolus CT protocol shows a significant cystic dilatation of the main pancreatic duct with linear parietal calcifications without mural nodules and/or areas of pathological
enhancement. On 1.5T MRI the lesion appears homogeneously hyperintense on the axial (c) and coronal (d) T2W images, and site of communication with the Wirsung is
recognizable on the MRCP sequences (arrow in e). At multiphase T1W breath-hold fat-suppressed 3D gradient-echo images after intravenous administration of gadolinium (Gd-
DTPA) (feh) the lesion doesn't exhibit enhancement neither restriction of diffusion on DWI with high b values (i) and ADC sequences (l).
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up for next three years.
Usually imaging shows a cystic mass with a thick wall that ex-
hibits mild enhancement after intravenous contrast injection.
6.1. Serous cystadenoma
Serous cystadenomas are benign cystic tumors (20% of allFig. 11. 75-years-old female patient with metastatic small cell lung cancer at 64-slice Split-
mass at the right upper lobe of the lung (a) and a heterogeneous metastasis in the liver anpancreatic cystic neoplasms), typically diagnosed incidentally in
asymptomatic patients, most frequently in older women, which do
not require surgical excision. The lesion appears as a cluster of cysts
well-defined (without visible communicationwith pancreatic duct)
with a high signal intensity on MRI T2W images (Figs. 7e8), with a
thin fibrous septa that can show delayed enhancement after
contrast medium administration. Two subtypes of lesions are
known: microcystic serous cystadenomas, composed of multiplebolus CT protocol during follow-up. Mixed phase shows the primitive inhomogeneous
d in the tail of the pancreas (b).
Fig. 12. 56-years-old female patient with previous excision of malignant melanoma of the back. 64-slice CT during follow-up in axial arterial phase (a), venous phase (b) and coronal
venous phase (c) shows a voluminous metastatic mass that exhibits inhomogeneous enhancement in the head of the pancreas with massive infiltration of adjacent vessels and
structures.
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central calcified scar, and macrocystic serous cystadenomas, un-
common, composed of large cysts (1e8 cm). A central calcified scar
is highly specific and best demonstrated at CT [49]. When associ-
ated with von HippeleLindau (VHL) disease, multifocal cystic le-
sions can involve the pancreatic gland diffusely [96].
The features in DWI and ADC are depending on the amount of
fibrous septa or fluid in the lesion; occasionally serous cys-
tadenomas with fibrous septa can show relatively higher signal
intensity on DWI and lower ADC values compared with non-
neoplastic cysts. On the bases of DWI the differential diagnosis
between these lesions and non-neoplastic cysts is difficult [49].6.2. Mucinous cystic neoplasm (mucinous cystadenoma/
cystadenocarcinoma)
Mucinous cystic neoplasm (10% of all pancreatic cystic neo-
plasms), are most frequently diagnosed in women (80%) in their
sixth decade of life [89,97] and are preferentially localized in body
and pancreatic tail without communication with pancreatic duct
[unlike intraductal papillary mucinous neoplasms (IPMNs)].
The lesion appears as a multilocular or unilocular or midly
septated cysts well-defined, usually >2 cm (Fig. 9). In relation to theFig. 13. 79-years-old male patient with previous duodeno-cefalo pancreatectomy for neuro
surgery (a); after 12 months, 18F-FDG PET-TC (b) shows a small area of hyperfixation suspic
values (c) and ADC map (d), confirms the PET-TC finding showing a circumscribed area ofdegree of hemorrhage or the amount of protein in themucoid cysts,
CT shows different levels of attenuation [96] and the lesion may be
hyperintense on T1W images.
Imaging is unable to distinguish cystadenoma from cys-
tadenocarcinoma, furthermore intracystic enhancing soft tissues,
invasion of adjacent organs and vascular invasion are suspicious for
malignancy, as metastatic disease too. The rare (16%) presence of
peripheral eggshell calcifications has a highly predictive value for
malignancy. DWI will not distinguish between mucinous cystic
neoplasm and non-neoplastic mucinous cystic neoplasm due to the
relatively high ADC values [49].6.3. Intraductal papillary mucinous tumor of the pancreas
IPMNs of the pancreas represent 20% of cystic pancreatic lesions
and occur more frequently in elderly men [86,94]. The histopath-
ologic characteristics of IPMNs are papillary growth and hyper-
production of mucina which causes dilatation of the main
pancreatic duct, its branches or both [49,50,97,98]. The character-
istic imaging feature of IPMNs is the communication of lesion with
pancreatic ducts, demonstrate on MRI [49], useful to differentiate
them from mucinous cystadenoma (Fig. 10).
IPMNs may frequently be multifocal and may have benign orendocrine tumor of the head of the pancreas at 64-slice Split-bolus CT protocol post-
ious for recurrence, next to the surgical clip. 3 T mpMRI including DWI with b ¼ 1000
restricition of diffusion (arrow in c and d).
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affects the main duct, the lesion is more likely to be malignant.
The features suggestive of invasive carcinoma are the large size
of the mass (>3 cm), presence of mural nodules, dilatation of the
main pancreatic duct > 1 cm and multifocal involvement [50].
DWI does not allow a differential diagnosis because IPMNs usu-
ally show an high ADC value even in cases of carcinomas in situ [49].
7. Metastases
Pancreatic metastases occur in 2e5% of all malignant neoplasms
and originate most frequently from renal cell carcinoma, lung car-
cinoma, breast carcinoma, colorectal carcinoma, ovarian carcinoma
and melanoma [99]. Imaging features are non-specific: metastases
can be solid or cystic, hypo- or hypervascular depending on primary
tumor and can be solitary (50e70%), multifocal or diffuse
[1,99e102] (Figs. 11e12).
8. Imaging after surgery
The knowledge of the type of surgical procedures (Whipple
procedure, distal pancreatectomy, central pancreatectomy or total
pancreatectomy) and the normal post-operative appearances are
essential for an accurate evaluation of the complications and
recurrent disease.
Several imaging techniques can be used after pancreatic surgery.
US plays a limited role in the early post-operative period useful only
for the peritoneal fluid detection.
In the immediate post-operative period the most common
findings are fluid peritoneal or peri-pancreatic collections,
increased density of the mesenteric fat tissue, reactive adenopathy
and pneumobilia; early and late surgical complications as anasto-
mosis leakage, pancreatico-jejunal fistula, peritonitis, abscess, an-
eurysms, anastomotic stenosis, perianastomotic ulcers, biloma and
intra-abdominal bleeding, are better detected on CT imaging.
CT represents the first choice for the evaluation of tumor
recurrence and for the assessment of lymph nodes and liver
metastasis [102].
MRI may be used as alternative imaging modality to CT or in
cases of inconclusive CT findings; furthermore, MRI combined with
functional DWI potentially provides helpulf information about
locally recurrent disease.
Also 18FDG PET is useful to detect recurrent disease after sur-
gery, but PET scan has to be performed for some months after
surgical treatment to avoid unspecific uptake of the radio-
compound due to inflammatory reaction after therapy (Fig. 13).
9. Conclusion
Imaging play an essential role in the assessment of neoplastic
and non-neoplastic diseases [103e106]. In order to a prompt and
accurate diagnosis and appropriate management of pancreatic le-
sions, it is crucial for radiologists to know the key findings of the
most frequent tumors of the pancreas and the current role of im-
aging modalities.
A multimodality approach is often helpful. If MDCT is the
preferred initial imaging modality in patients with clinical suspi-
cion for pancreatic cancer, mpMRI provides essential information
for the detection and characterization of a wide variety of pancre-
atic lesions and can be used as a problem-solving tool for diagnosis
and during follow-up.
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